key: cord-0833322-ggopcuei
authors: Sit, C.; Effiong, I.; Bradley, M.; Cerato, A. M.; Hogan, H.; Monds, T.; Pratt, A.; Redway, A.; Wu, C. Qiong
title: OA10.04 COVID-19 Vaccine Acceptance and Communications Effectiveness Amongst Canadian Lung Cancer Patients.
date: 2021-10-31
journal: Journal of Thoracic Oncology
DOI: 10.1016/j.jtho.2021.08.067
sha: fd8260c762f6ea8f7e63094a6d3ae73e4b7ce256
doc_id: 833322
cord_uid: ggopcuei

nan

forms of one pagers, brochures, and a quarterly educational newsletter. The program seeks to determine if empowering patients and caregivers with these resources affects the treatment journey. Methods: Data was collected as patient reported biomarker testing, history of all treatments received, and clinical trial participation through phone or email contact from 2018-2020. Data was interpreted and transformed using mean values to account for longitudinal consistency. Repeat patients or caregiver contacts were treated as separate and individual data points. Clinical trial accrual rates were measured only taking into account patients or caregivers who identified clinical trials as a potential treatment option. Results: As the years progressed, patients and caregivers reported increased usage of precision medicine as measured by targeted and immuno-therapy usage and biomarker testing rates (Table) . Additionally, clinical trial accrual rates remained higher than the national average and increased each year (Table. Increased participation since program launch, despite the impact of the COVID-19 pandemic, suggests a positive impact of the service on a patient's treatment journey. understanding and communications. Methods: OBJECTIVE -A quantitative patient survey was conducted by Lung Cancer Canada to assess Canadian lung cancer patient's acceptance of the COVID-19 vaccine and determine their viewpoint around communication on the rollout process. METHODOLOGY -An iterative approach was used in the study design. A focus group made up of lung cancer patients was convened to explore their thoughts around the topic. Their thoughts and words were used to develop a patient-centred quantitative survey. The survey was fielded digitally and promoted using direct email and social media platforms. The results were discussed and analyzed by the focus group.

Results: The survey was fielded between February 11th and 16th 2021. 124 Canadian lung cancer patients responded to the survey. 92% of lung cancer patients indicated they would receive the vaccine immediately if given. However, when asked about their understanding of whether or not lung cancer patients were part of those identified as a priority population, only 37% believed that they would receive the vaccine as part of a priority population. 38% were unsure and 24% of patients believed that they would receive it with the general population. In terms of communication, the survey respondents indicated a high level of dissatisfaction across various stakeholder groups in regards to how they are addressing the needs of cancer patients in the COVID-19 vaccine rollout, with elected officials 81%, federal government 77%, provincial government 74%, professional medical associations 58%, provincial cancer agencies 55% and national cancer agencies 52%. They also indicated they received information concerning the vaccine from various sources including the federal government 40%, provincial government 50%, healthcare providers 21%, traditional media 60% and social media 40%. The numbers signify the important role these sources play in the provision of information.

The results indicate vaccine acceptance is actually quite high among lung cancer patients in Canada, but there are critical gaps in communication. Due to the unprecedented nature of the pandemic, it is understandable that information changes and updates happen quickly. The results of the survey underscore the need for collaborative and synergistic communications between all levels of government and cancer care teams to provide patients with consistent and correct information on the vaccine rollout. It is also important to note the changing information consumption environment. Although traditional media is still an important source of information, patients are also getting their information regarding the vaccine on social media. It is important for both government and cancer care providers to recognize and utilize "where patients are at" communication vehicles beyond traditional media in order to both reach and address patient concerns. 

Introduction: Neoadjuvant immune checkpoint inhibitor treatment is a promising approach for resectable cancer. The optimal treatment regimen has yet to be determined